Compare · DXCM vs HIND
DXCM vs HIND
Side-by-side comparison of DexCom Inc. (DXCM) and Vyome Holdings Inc. (HIND): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HIND operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.31B, about 2016.9x HIND ($14.0M).
- Over the past year, DXCM is down 18.0% and HIND is down 77.7% - DXCM leads by 59.7 points.
- DXCM has hit the wire 6 times in the past 4 weeks while HIND has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for HIND).
- Company
- DexCom Inc.
- Vyome Holdings Inc.
- Price
- $73.36+2.55%
- $2.15-1.38%
- Market cap
- $28.31B
- $14.0M
- 1M return
- +6.92%
- -0.46%
- 1Y return
- -18.05%
- -77.70%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest HIND
- Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
- Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Vyome Holdings Inc.
- Vyome Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
- Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
- SEC Form DEF 14A filed by Vyome Holdings Inc.
- Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
- SEC Form PRE 14A filed by Vyome Holdings Inc.
- SEC Form 10-K filed by Vyome Holdings Inc.